Recent Analysts’ Ratings Changes for Viridian Therapeutics (VRDN)

Viridian Therapeutics (NASDAQ: VRDN) has recently received a number of price target changes and ratings updates:

• 7/12/2026 – Viridian Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 6/30/2026 – Viridian Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/30/2026 – Viridian Therapeutics had its price target raised by Truist Financial Corporation from $35.00 to $38.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $39.00 price target on the stock.
• 6/30/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $34.00 to $35.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – Viridian Therapeutics had its price target raised by Wedbush from $32.00 to $43.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Viridian Therapeutics was upgraded by Wells Fargo & Company from “equal weight” to “overweight”. They now have a $31.00 price target on the stock, up from $20.00.
• 6/29/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $32.00 price target on the stock.
• 6/14/2026 – Viridian Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.

Insider Activity

In related news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the acquisition, the director owned 5,090,928 shares in the company, valued at $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.40% of the stock is owned by insiders.

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.